Clinical Research Directory

Inclusion Criteria * Histological evidence of NAFLD and enrollment in NASH CRN Database Study * Type 2 DM treated with diet or a stable dose of non-insulin sensitizing oral hypoglycemic agents for \> 3 mo. * Hemoglobin HbA1c level ≤ 8 % * Serum ALT levels ≥1.3 x ULN * Between 18-65 years of age Exclusion Criteria * Hereditary hemochromatosis or hepatic iron overload defined as any of the following: * 2+ iron on hepatic iron staining * Hepatic Iron Index ≥ 1.9 * C282Y homozygous or C282Y/H63D compound heterozygous HFE genotype * Use of insulin or thiazolidinediones for the treatment of diabetes * Use of anti-NASH drugs (thiazolidinediones, vitamin E, UDCA, SAM-e, betaine, milk thistle, gemfibrozil, anti-TNF therapies, probiotics) * Serum ferritin \<50μg/L * Serum transferrin-iron saturation \<10 % * Hemoglobin \<10 mg/L * Hematocrit \<38 % * Voluntary blood donation or therapeutic phlebotomy within the previous twelve months (except routine lab tests) * Pregnant or lactating women * Prior history of coronary artery disease, myocardial infarction, exertional dyspnea or chronic chest pain at rest. * Evidence of myocardial infarction as determined by an ECG